Q1 2025 Earnings Call Transcript May 13, 2025 Acumen Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

This kitchen staple is backed by science for its many health benefits, and you probably already have it on hand.

We recently published a list of 10 Low Risk High Reward Stocks Set to Triple by 2030. In this article, we are going to take a ...

Topline data from pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN on track for Q4 2025 Completed ...

On track to report final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP in Q2 2025 - - Plans to initiate Phase 2 clinical trial evaluating VG-3927 in Alzheimer's disease ...

WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology ...

Detailed price information for Lantheus Holdings (LNTH-Q) from The Globe and Mail including charting and trades.

Medications like donanemab (Kisunla) and lecanemab (Leqembi) target amyloid plaques that build up in the brain due to Alzheimer's disease.

RRB JE CBT 2 Answer Key 2025: The Railway Recruitment Board (RRB) has released the provisional answer key for Junior Engineer posts. Now candidates will be able to estimate their probable score ...

33%), which has risen from $1.07 billion since 2020. They also have $6.479 billion of goodwill on the balance sheet out of total assets worth just over $28 billion. Their current debt, most of ...